Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

Archives of Neurology

Volumn 61, Issue 10, 2004, Pages 1563-1568

  Olanow, C W ^a   Kieburtz, K ^b   Stern, M ^c   Watts, R ^d   Langston, J W ^d   Guarnieri, M ^e   Hubble, J ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EMORY UNIVERSITY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; FALLING; FATIGUE; FEMALE; HEADACHE; HEALTH SURVEY; HUMAN; INSOMNIA; LEG EDEMA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREMOR; URINARY TRACT INFECTION; URINE COLOR;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 5344247928     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.10.1563     Document Type: Article

References (21)

1. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disabiity and levodopa metabolism in parkinsonian patients. Neurology. 1994;44:77-80.
2. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharm. 1996;19:283-296.
3. Rinne UK, Larsen JP, Siden A; Worm-Petersen; Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:1309-1314.
4. Parkinson's Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42:747-755.
5. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology. 2000;55(suppl 4):72-81.
6. Waters CH, Kurth M, Bailey P, et al; Tolcapone Stable Study Group. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology. 1997;49:665-671.
7. Fahn S, Elton R; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale: Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163, 293-304.
8. Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson's disease: a study of outsubject clinic attenders. Mov Disord. 1997;12:916-922.
9. Ware JE. How to Score the SF-36 Health Survey, Manual and Interpretation Guide. Boston, Mass: Health Institute, New England Medical Center; 1993:18-19.
10. Martin LM, Budhiarso I, Bushnell D, Hogan T. Parkinson's Symptom Inventory (PSI) Analytic Results of Field Test. Health Research Associates; December 1, 1997. N0. 96-15B.
11. Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord. 1997;12:277-284.
12. Hogl BE, Gomez-Arevalo G, Garcia S, et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. 1998;50:1332-1339.
13. Parkinson's Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
14. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med. 2000;342:1484-1491.
15. Wheatly K, Stowe RB, Clarke CE, Hills RK, Williams AC, Gray R. Evaluating drug treatments for Parkinson's disease: how good are the trials? BMJ. 2002;324:1508-1511.
16. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738-750.
17. Welsh MD, Dorflinger E, Chernik D, Waters C. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Mov Disord. 2000;15:497-502.
18. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with current models of the basal ganglia. Ann Neurol. 2000;47(4, suppl 1):S22-S34.
19. Bedard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys: correlation with [3H]spiperone binding. Brain Res. 1986;379:294-299.
20. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234-241.
21. Smith LA, Jacobson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produces continuous dopaminergic stimulation and reduces dyskinesia induction in MPTP-treated drug naïve primates. Mov Disord. In press.